Latest Breaking News On - Davidc hanley - Page 1 : comparemela.com

Nuvation Bio : Ongoing enrollment in Phase 1/2 study of lead investigational compound NUV-422 for the treatment of adult patients with malignant gliomas; protocol amendment submitted to expand into additional cancers (Form 8-K)

Nuvation Bio : Ongoing enrollment in Phase 1/2 study of lead investigational compound NUV-422 for the treatment of adult patients with malignant gliomas; protocol amendment submitted to expand into additional cancers (Form 8-K)
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesSan franciscoLeo vartorellaNuvation bioDavidc hanleyRegulatory affairsNuvation bio incDrug administrationMedivation incClinical developmentChief technical operations officerDavid hungChief technical operationsClinical operationsQuarterly report

BioSpace Movers & Shakers, June 4

Biopharma and life sciences organizations strengthen their leadership teams and board with these Movers & Shakers.

Wills eye hospitalUnited statesM karen newell rogersMyers squibbDenise straussMarc semigranDavidc hanleyEric castaldiJen hongMeagher flomMarc massiotNewell rogersRobin knifsendTheodore reissJeff cruikshankEvelo biosciences

BioSpace Movers & Shakers, June 4

Published: Jun 03, 2021 By Alex Keown 180 Life Sciences Russell T. Ray and Teresa DeLuca were appointed to the board of directors of 180 Life Sciences. Ray was formerly Managing Director and co-Head of Global Health Care at Credit Suisse First Boston Corporation. More recently, Ray was a Partner and Senior Advisor to HLM Venture Partners, a health care-focused venture capital firm. He currently serves on the board of directors of Merrimack Pharmaceuticals, Inc. DeLuca comes to 180 Life Sciences as both a public independent board director and former senior executive Chief Medical Officer. Her most recent role was at Columbia University as Managing Director of NY Life Science Venture Fund.

Wills eye hospitalUnited statesM karen newell rogersMyers squibbDenise straussMarc semigranDavidc hanleyEric castaldiJen hongMeagher flomMarc massiotNewell rogersRobin knifsendTheodore reissJeff cruikshankEvelo biosciences

Nuvation Bio Appoints David C Hanley, Ph D , as Chief Technical Operations Officer

Published: Jun 01, 2021 Experienced technical operations and CMC leader brings scientific and strategic expertise in oncology drug development and life cycle management NEW YORK, June 1, 2021 /PRNewswire/ Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of David C. Hanley, Ph.D., as Chief Technical Operations Officer, joining the Company s executive management team. In his new role, Dr. Hanley will oversee all early- and late-stage pharmaceutical development and operations, including supply chain, product development and manufacturing efforts, and work closely on commercial planning with Quality, Regulatory Affairs, Clinical Development and Clinical Operations teams.

New yorkUnited statesSan franciscoLeo vartorellaNuvation bioDavidc hanleyHead of global pharmaceutical developmentMedicines companyRegulatory affairsUniversity of utahVirginia commonwealth universityDrug administrationGlobal pharmaceutical developmentNuvation bio incPrnewswire nuvation bio incRadius health inc